Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 4:2019:7434376.
doi: 10.1155/2019/7434376. eCollection 2019.

The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis

Affiliations
Review

The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis

Francesco Moroni et al. Mediators Inflamm. .

Abstract

Atherosclerosis is one of the leading causes of death and disability worldwide. It is a complex disease characterized by lipid accumulation within the arterial wall, inflammation, local neoangiogenesis, and apoptosis. Innate immune effectors, in particular monocytes and macrophages, play a pivotal role in atherosclerosis initiation and progression. Although most of available evidence on the role of monocytes and macrophages in atherosclerosis is derived from animal studies, a growing body of evidence elucidating the role of these mononuclear cell subtypes in human atherosclerosis is currently accumulating. A novel pathogenic role of monocytes and macrophages in terms of atherosclerosis initiation and progression, in particular concerning the role of these cell subsets in neovascularization, has been discovered. The aim of the present article is to review currently available evidence on the role of monocytes and macrophages in human atherosclerosis and in relation to plaque characteristics, such as plaque neoangiogenesis, and patients' prognosis and their potential role as biomarkers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the main findings of human studies concerned with monocytes and macrophages and atherosclerosis. In subjects with high risk plaques, intermediate CD14hiCD16+ monocytes are enriched in the circulation. Less evidence is available for osteogenic biomarker expressing CD14+BAP+OCN+ monocytes, which appear to be enriched in the peripheral blood of subjects with large necrotic cores within the plaque. On the other hand, in subjects with highly neovascularized plaques, classical CD14hiCD16 monocytes are reduced in the circulation, possibly due to the redistribution into the plaque. Monocytes are activated by OxLDL acting through pattern recognition receptors (PRR). The PRR most frequently implicated in human cardiovascular disease is TLR4. Monocytes locally differentiate into macrophages, which take up OxLDL by means of scavenging receptors. Cholesterol is then transported outside the cell through specialized transporters, including ABCA1. ABCA1 transports cholesterol to nascent HDLs. When cholesterol loading exceeds macrophage efflux capability, the macrophage turns into a foam cell. Human plaques are enriched with NF-kB-expressing macrophages.

References

    1. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260–1344. doi: 10.1016/S0140-6736(17)32130-X. - DOI - PMC - PubMed
    1. Chatzizisis Y. S., Coskun A. U., Jonas M., Edelman E. R., Feldman C. L., Stone P. H. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. Journal of the American College of Cardiology. 2007;49(25):2379–2393. doi: 10.1016/j.jacc.2007.02.059. - DOI - PubMed
    1. Dai G., Kaazempur-Mofrad M. R., Natarajan S., et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(41):14871–14876. doi: 10.1073/pnas.0406073101. - DOI - PMC - PubMed
    1. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B., Emberson J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590. doi: 10.1016/S0140-6736(12)60367-5. - DOI - PMC - PubMed
    1. Turnbull F., Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–1535. - PubMed

MeSH terms